Skip to main content
Premium Trial:

Request an Annual Quote

Emerald BioStructures, UCB Expand Drug Discovery Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB today said that they have a achieved a second milestone in their ongoing collaboration and have expanded the alliance.

Bainbridge Island, Wash.-based Emerald said that it and UCB researchers have solved high-resolution X-ray crystallographic structures of multiple targets and have identified a unique lead series of small molecules. The firm said that it achieved that milestone within two years, since the firms initiated their collaboration in January 2009.

Emerald also said that the firms have decided to expand the agreement, though it provided few details. The expansion will result in undisclosed research fees, a milestone payment, and royalties. Emerald said that the financial terms would support multiple full-time researcher equivalents at the firm.